Nanobodies: Pioneering Next‐Generation Tools in Modern Medicine

Nanobodies, also known as single-domain antibodies or Variable Heavy domain of Heavy chain antibody, are unique antibody fragments derived from camelid heavy-chain antibodies. Due to their small size, stability, and high specificity, nanobodies have gained significant attention for therapeutic and diagnostic applications across various diseases, including cancer, infectious diseases, and neurodegenerative disorders. Their structural simplicity allows efficient production in microbial systems, offering a scalable and cost-effective alternative to traditional monoclonal antibodies. In cancer, nanobodies are effective for targeted drug delivery, improved tumor imaging, and enhanced penetration into solid tumors. Moreover, the versatility of engineered nanobodies extends to the treatment of neurodegenerative diseases, where they may possess the ability to cross the blood-brain barrier, allowing for targeted delivery within the central nervous system. Additionally, nanobodies demonstrate promise in neutralizing toxins, inhibiting inflammatory responses, and modulating the immune system, showcasing their adaptability in treating infectious and inflammatory diseases. Despite their advantages, challenges such as limited half-life, potential immunogenicity, and regulatory hurdles remain. This review explores the structural and functional characteristics of nanobodies, their applications in various disease therapies, and current strategies to overcome these therapeutic limitations.